|
| Press Releases |
|
 |
|
| Wednesday, August 3, 2022 |
|
|
Zhaoke Ophthalmology Completed Patient Enrollments for the Phase III Clinical Trials of the Myopia Progression Treatment Drug NVK002 |
| Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or "the Company", SEHK: 6622), a leading ophthalmic pharmaceutical company dedicated to the research and development more info >> |
|
| Monday, November 15, 2021 |
|
|
兆科眼科获选于2021年美国眼科学会年会Eyecelerator@AAO上发表演讲 |
| 致力于眼科疗法的研究、开发及商业化，以满足巨大医疗需求缺口的领先眼科制药企业兆科眼科有限公司（「兆科眼科」；香港联交所股份代号：6622）获选于2021年11月11日在美国新奥尔良举行的2021年美国眼科学会年会Eyecelerator@AAO上发表演讲。 more info >> |
|
|
兆科眼科獲選於2021年美國眼科學會年會Eyecelerator@AAO上發表演講 |
| 致力於眼科療法的研究、開發及商業化，以滿足巨大醫療需求缺口的領先眼科製藥企業兆科眼科有限公司（「兆科眼科」；香港聯交所股份代號：6622）獲選於2021年11月11日在美國新奧爾良舉行的2021年美國眼科學會年會Eyecelerator@AAO上發表演講。 more info >> |
|
| Monday, May 24, 2021 |
|
|
兆科眼科(6622.HK)两项产品通过国家药监局药品注册现场核查及GMP符合性检查 |
| 致力于眼科疗法的研究、开发及商业化的眼科制药公司——兆科眼科有限公司(「兆科眼科」或「公司」；股份代号：6622)，宣布两项药品——贝美素噻吗洛尔滴眼液(在中国用于治疗青光眼的潜在首仿药 more info >> |
|
|
兆科眼科(6622.HK)兩項產品通過國家藥監局藥品註冊現場核查及GMP符合性檢查 |
| 致力於眼科療法的研究、開發及商業化的眼科製藥公司——兆科眼科有限公司(「兆科眼科」或「公司」；股份代號：6622)，宣佈兩項藥品——貝美素噻嗎洛爾滴眼液(在中國用於治療青光眼的潛在首仿藥 more info >> |
|
|
Two Products of Zhaoke Ophthalmology (6622.HK) Passes On-Site Inspection for Drug Registration by National Medical Products Administration and GMP Compliance Inspection by Guangdong Medical Products Administration |
| Zhaoke Ophthalmology Limited ("Zhaoke Ophthalmology" or the "Company"; stock code: 6622), an ophthalmic pharmaceutical company dedicated to the research, development and commercialization of therapies that address significant unmet medical needs more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
International Women's Day: Why Menopause May Be a Missed Cardiovascular Risk Window
Mar 6, 2026 20:00 JST
|
|
|
Xunce (3317.HK) Released Profit Alert: Revenue Doubles, Surpasses Expectations by a Wide Margin, China's Palantir Rises!
Mar 6, 2026 18:23 HKT/SGT
|
|
|
迅策(3317.HK)發佈盈利預告：營收翻翻 大超預期 中國版Palantir崛起！
Mar 6, 2026 18:17 HKT/SGT
|
|
|
迅策(3317.HK)发布盈利预告：营收翻翻 大超预期 中国版Palantir崛起！
Mar 6, 2026 18:00 HKT/SGT
|
|
|
香港實現綠色甲醇首船加注 推動國際航運中心綠色轉型
Mar 6, 2026 15:40 HKT/SGT
|
|
|
香港实现绿色甲醇首船加注 推动国际航运中心绿色转型
Mar 6, 2026 15:31 HKT/SGT
|
|
|
Hong Kong Completes First Green Methanol Bunkering, Driving Green Transformation of Its International Shipping Hub
Mar 6, 2026 15:05 HKT/SGT
|
|
|
Hong Kong Tech Innovators Drive Success at Mobile World Congress and 4YFN Barcelona 2026
Mar 6, 2026 13:08 HKT/SGT
|
|
|
U.S. Polo Assn. Expands Collegiate Partnership Program to Record 70 Teams for 2026 Season
Mar 6, 2026 12:12 HKT/SGT
|
|
|
Anime Tokyo Station: "That Time I Got Reincarnated as a Slime" Special Exhibition, February 21 to May 24, 2026
Mar 6, 2026 10:00 HKT/SGT
|
|
|
TANAKA Develops World's First High-Performance Palladium Hydrogen Permeable Membrane Exhibiting High Hydrogen Purification Performance at Temperatures around 100 degrees C
Mar 5, 2026 22:00 JST
|
|
|
美國馬球協會擴大大學合作計畫 2026賽季隊伍數創紀錄達70支
Mar 5, 2026 20:00 HKT/SGT
|
|
|
美国马球协会扩大大学合作计划，2026赛季参赛队伍创纪录达70支
Mar 5, 2026 20:00 HKT/SGT
|
|
|
Lancaster Resources Announces Resignation of Penny White and the Addition of Rob Heaslop to the Board of Directors
Mar 5, 2026 17:29 HKT/SGT
|
|
|
CMS (867.HK/8A8.SG): Self-Developed INHBE-Targeting siRNA Drug Received IND Approval for Overweight/Obesity
Mar 5, 2026 17:00: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
